Lupin FY21 Annual Report Takeaways 🧬
'We have 3 focus areas for Complex Generics - Inhalation, Biosimilars & Complex Injectables.'
Hit the 'retweet' & help us educate more investors.
A Thread 🧵👇
'We have 3 focus areas for Complex Generics - Inhalation, Biosimilars & Complex Injectables.'
Hit the 'retweet' & help us educate more investors.
A Thread 🧵👇
1/ The Journey since Inception in 1968
Among the world leaders in anti-Tuberculosis drugs & Cephalosporins: Has capabilities in complex chemistry & biotechnology.
Multiple plants (15 in total) & 7 R&D centers, located across the globe: 20K+ employees.
Among the world leaders in anti-Tuberculosis drugs & Cephalosporins: Has capabilities in complex chemistry & biotechnology.
Multiple plants (15 in total) & 7 R&D centers, located across the globe: 20K+ employees.
2/ Numbers that matter
Flat rev
18% EBITDA margin
Pat up 34% (deleveraging)
1432cr spends on R&D (9.6% of sales)
627cr capex spends
6th rank in IPM (11 brands among the top 300)
3rd rank by prescription in 🇺🇸
886 active patents
19 ANDA approvals in FY21 | launched 15
Flat rev
18% EBITDA margin
Pat up 34% (deleveraging)
1432cr spends on R&D (9.6% of sales)
627cr capex spends
6th rank in IPM (11 brands among the top 300)
3rd rank by prescription in 🇺🇸
886 active patents
19 ANDA approvals in FY21 | launched 15
3/ From the desk of the Chairman & the Vice-Chairman
- Continued building on women's health business in 🇺🇸, ramped up in Albuterol & increased market share in Levothyroxine
- Made significant progress in complex generics platforms across inhalation, biosimilars & Injectables
- Continued building on women's health business in 🇺🇸, ramped up in Albuterol & increased market share in Levothyroxine
- Made significant progress in complex generics platforms across inhalation, biosimilars & Injectables
4/ From the desk of the CEO & MD
- Total of 168 products in 🇺🇸 & among the top 3 in 122 of them
- Got the approval to launch Etarnacept in Europe & BLA filling review for pegfilgrastim in progress: Validates the capabilities
- Got the UK authorization for Fostair: 1st generic
- Total of 168 products in 🇺🇸 & among the top 3 in 122 of them
- Got the approval to launch Etarnacept in Europe & BLA filling review for pegfilgrastim in progress: Validates the capabilities
- Got the UK authorization for Fostair: 1st generic
5/ Strategy
- Tapping specialty generics: multiple billion $ opportunities
- Cost optimization: increasing R&D productivity & better operational focus
- Build product portfolio of select therapies in countries where competition is low: Neurology in 🇪🇺,🇬🇧, Women's health in 🇺🇸
- Tapping specialty generics: multiple billion $ opportunities
- Cost optimization: increasing R&D productivity & better operational focus
- Build product portfolio of select therapies in countries where competition is low: Neurology in 🇪🇺,🇬🇧, Women's health in 🇺🇸
6/ US market
- 36% of rev, 53 products ranked #1
- Pegfilgrastim could be launched by FY23, Started Phase 3 studies for Ranibizumab
- Received 5 FTF approvals & 4 shared FTF approvals in FY21
- Sales should be back to pre-covid levels by this year.
- 36% of rev, 53 products ranked #1
- Pegfilgrastim could be launched by FY23, Started Phase 3 studies for Ranibizumab
- Received 5 FTF approvals & 4 shared FTF approvals in FY21
- Sales should be back to pre-covid levels by this year.
7/ The Indian Pharma Market (IPM)
- 35% of rev, Have consistently outperformed the IPM in the last 5yrs: 3.6% market share
- 7000+ field force, 65% rev from chronic (4th largest) & rest acute
- Market share therapy wise given 👇 : Leader in Anti-TB, 2nd in Respiratory
- 35% of rev, Have consistently outperformed the IPM in the last 5yrs: 3.6% market share
- 7000+ field force, 65% rev from chronic (4th largest) & rest acute
- Market share therapy wise given 👇 : Leader in Anti-TB, 2nd in Respiratory
8/ Growth markets & EMEA
- 4th largest in 🇦🇺, 2nd largest ophthalmic company in 🇲🇽, 2nd largest in Phillippines reference market, 4th in 🇿🇦 by prescriptions
- 9% of sales from 🇪🇺 & 🇬🇧
New complex product launches are key contributors to growth.
- 4th largest in 🇦🇺, 2nd largest ophthalmic company in 🇲🇽, 2nd largest in Phillippines reference market, 4th in 🇿🇦 by prescriptions
- 9% of sales from 🇪🇺 & 🇬🇧
New complex product launches are key contributors to growth.
9/ API: Captive consumption+ External sales
- 9% of rev, working on increasing the portfolio & capacities
- Expertise in fermentation tech helps to be at the forefront of the battle against TB & ARV: development pipeline is in focus
- 6 of the API plants are approved by WHO
- 9% of rev, working on increasing the portfolio & capacities
- Expertise in fermentation tech helps to be at the forefront of the battle against TB & ARV: development pipeline is in focus
- 6 of the API plants are approved by WHO
10/ Risks & how they are working towards mitigating them.
11/ From the desk of the CFO
- 9 of the 15 sites are USFDA approved
- Have marketing offices in 23 countries, that will help augment market share going forward
- Multiple sourcing strategies: Have long term contracts with raw material suppliers
- 9 of the 15 sites are USFDA approved
- Have marketing offices in 23 countries, that will help augment market share going forward
- Multiple sourcing strategies: Have long term contracts with raw material suppliers
12/ Manufacturing capabilities
- Augmented capacities: API, multi-fold expansion in Biotech Drug Substance (to undergo inspections by 🇪🇺' EMA & 🇯🇵's PMDA soon), Inhalation
- Various initiatives to adopt digitization & automation
- 2600+ employees in quality: a key focus.
- Augmented capacities: API, multi-fold expansion in Biotech Drug Substance (to undergo inspections by 🇪🇺' EMA & 🇯🇵's PMDA soon), Inhalation
- Various initiatives to adopt digitization & automation
- 2600+ employees in quality: a key focus.
13/ Finally, the most important thing: Intellectual capital.
A strong pipeline indeed, with strong compliance (as the future USFDA inspections will tell us) will go a long way: Multifold Scale-up potential.
End of Thread.
A strong pipeline indeed, with strong compliance (as the future USFDA inspections will tell us) will go a long way: Multifold Scale-up potential.
End of Thread.
Lupin Q4FY21 results.
Also, if one is interested in Lupin's FY20 Annual report takeaways, we covered it here
jstinvestments.com
Also, if one is interested in Lupin's FY20 Annual report takeaways, we covered it here
jstinvestments.com
Loading suggestions...